Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
"I don't want to do business at all because it is a national security threat," Trump told reporters.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Trump's is due to visit Copenhagen early next month, when the Arctic will be on the agenda in meetings.World Politicsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
First-time entrepreneur Ethan Perlstein has a unique strategy to get ahead: Telling the truth.
"To beat me, any potential rivals would have to out-transparency me," said Perlstein, in an interview with CNBC. "And that's anathema to the status quo."
Perlstein's approach with his start-up, Perlara, which is working with families to find cures for rare diseases, is radically different from how most start-ups operate.
Investors and boards typically pressure start-ups to stay quiet. A lot of entrepreneurs also believe that secrecy will help them quietly sneak up on incumbents. Plus, it can be a bit embarrassing to talk about non-existent revenues in the early days of a company. It's a lot easier to win investors by selling a big vision.
Perlstein wants to start a movement to do just the opposite: Share numbers, share data, share everything. That includes saying what he thinks, even if that means pissing a few people off. (Perlstein almost certainly raised a few eyebrows when he referred to tech investors as little more than "biocurious," while insisting that the best way they could help him is to cut the platitudes and cut him a check).
To test out Perlstein's commitment to openness, CNBC shared a handful of questions that would get a polite but firm "no comment" from most founders. He shared his responses via email:
Perlara has raised just shy of $10 million in venture capital since its 2014 inception. It is a graduate of one of Silicon Valley's most competitive accelerator programs, Y Combinator.
It might seem a little nuts for an early-stage start-up to share these metrics publicly. But Perlstein has his reasons:
While his approach might seem admirable, not everyone agrees that it's the right thing to do.
"Things could change for a start-up from month-to-month," said Steve Kraus, a health and technology investor with Bessemer Venture Partners. One big customer win or loss could change things, and make last week's numbers irrelevant. So it might be advisable to never share them in the first place.
Kraus is also skeptical that it will give Perlara a competitive edge.
"And as for getting an edge for transparency, I'm not so sure about that," he added. In pharma, said Kraus, sharing data might open up a company to more competition from incumbents, who could then deliver a better, faster product.
Others believe there's a middle ground between Perlara's total transparency and the prevailing culture of secrecy. Evidation Health's Christine Lemke, who is also an angel investor, said her start-up makes it a policy to share as much as they can with potential recruits. Evidation works with other health start-ups to help them generate evidence to back-up their claims.
But getting approval to share revenues publicly would be another story.
And she wonders whether companies would regret taking that approach if their company goes through a bad patch.
"I bet that transparency goes away if your revenue takes a nosedive," she said.